mind body glp 1 Dual-action obesity drug rewires brain circuits for appetite GLP-1 Support – Amino Complex,

Other important contributing factors are eating disorders and depression, which are more common in patients with T1D compared to the overall population ( Figure 1 Obesity increases the risk of obesity-related as well as diabetes-related complications in patients with T1D, including micro- and macrovascular complications, various types of cancer, and overall mortality ( Figure 1 )

Exenatide extended-release (ER) , taken weekly: FDA-approved under the brand name Bydureon to treat type 2 diabetes

However, this is optional for plans, not mandated

Convergent evidence shows that (i) obesity is associated with reduced striatal D2 receptor availability [27], (ii) high-glycemic/rapid-absorption carbohydrates are plausible pharmacokinetic drivers of addictive-like responses [25], and (iii) ultra-processed foods high in refined carbohydrates and/or fat are disproportionately linked to addictive-like eating behaviors [28]

Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, Sugg J, Parikh S

In the trials, participants who took the highest dose reduced their A1C values by an average of 2.0%